Skip to main content
September 17, 2021

Journey Clinical Raises $3M to Allow Psychotherapists to Offer Psychedelic Therapies

CFO and Controllership Advisory

Journey Clinical recently raised $3 million during its Series A funding round led by Fifty Years. This funding will be put towards helping psychotherapists to better treat their patients. Exbo Group provides ongoing financial diligence support to Journey.

Key investors included Neo Kuma Ventures, Palo Santo, PsyMed Ventures, Lionheart Ventures, Christina Sass, Edvard Engesæth and Hans Gangeskar.

Journey Clinical’s “decentralized clinic model” provides patients with access to legal psychedelic therapy treatments through their psychotherapists. John Sabbagh, the Co-Founder and CEO of Journey Clinical, said, “We are on the verge of a paradigm shift in the field of mental health. Psychedelic-assisted psychotherapies are one of the most promising new means of treatment available.”

Read news article